PAP
MREO

Persistent Asset Partners’s Mereo BioPharma MREO Stock Holding History

Persistent Asset Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-113,247
Closed -$273K – 221
2025
Q1 		$255K Buy
+113,247
New +$320K 0.21% 89

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Persistent Asset Partners's MREO Position: Q2 2025 in Review

Persistent Asset Partners sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 113,247 shares — an estimated $273K sold.

Persistent Asset Partners first reported a position in MREO in Q1 2025 and held it in 1 quarter. The position peaked at $255K in Q1 2025. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

  • Persistent Asset Partners reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 113,247 Mereo BioPharma shares in Q2 2025, an estimated $273K.
  • Persistent Asset Partners first reported a position in Mereo BioPharma in Q1 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Mereo BioPharma position peaked at $255K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.